Spero Therapeutics Inc Received its Third Buy in a Row

By Austin Angelo

After Oppenheimer and Cowen & Co. assigned a Buy rating to Spero Therapeutics Inc in the last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Louise Chen maintained a Buy rating on Spero Therapeutics Inc (NASDAQ: SPRO) today and set a price target of $27. The company’s shares opened today at $15.69.

Chen observed:

“There will be one oral presentation and seven poster presentations on SPRO’s SPR741 at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held between 4/21-4/24.”

According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -11.8% and a 34.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Paratek Pharmaceuticals, and Theravance Biopharma.

Currently, the analyst consensus on Spero Therapeutics Inc is Strong Buy and the average price target is $28.50, representing an 81.6% upside.

In a report issued on April 3, Oppenheimer also reiterated a Buy rating on the stock with a $30 price target.

The company has a one-year high of $19 and a one-year low of $9.66. Currently, Spero Therapeutics Inc has an average volume of 32.71K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spero Therapeutics, Inc. develops novel therapies for the treatment of resistant bacterial infections. It engages in the research and development of mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections.